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PAT4 levels control amino-acid sensitivity of rapamycin-
resistant mTORC1 from the Golgi and affect clinical outcome
in colorectal cancer
S-J Fan1,3, C Snell2,3, H Turley2, J-L Li2, R McCormick2, SMW Perera1, S Heublein1, S Kazi1, A Azad1, C Wilson1, AL Harris2 and
DCI Goberdhan1
Tumour cells can use strategies that make them resistant to nutrient deprivation to outcompete their neighbours. A key
integrator of the cell’s responses to starvation and other stresses is amino-acid-dependent mechanistic target of rapamycin
complex 1 (mTORC1). Activation of mTORC1 on late endosomes and lysosomes is facilitated by amino-acid transporters within
the solute-linked carrier 36 (SLC36) and SLC38 families. Here, we analyse the functions of SLC36 family member, SLC36A4,
otherwise known as proton-assisted amino-acid transporter 4 (PAT4), in colorectal cancer. We show that independent of other
major pathological factors, high PAT4 expression is associated with reduced relapse-free survival after colorectal cancer surgery.
Consistent with this, PAT4 promotes HCT116 human colorectal cancer cell proliferation in culture and tumour growth in
xenograft models. Inducible knockdown in HCT116 cells reveals that PAT4 regulates a form of mTORC1 with two distinct
properties: ﬁrst, it preferentially targets eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and second,
it is resistant to rapamycin treatment. Furthermore, in HCT116 cells two non-essential amino acids, glutamine and serine,
which are often rapidly metabolised by tumour cells, regulate rapamycin-resistant mTORC1 in a PAT4-dependent manner.
Overexpressed PAT4 is also able to promote rapamycin resistance in human embryonic kidney-293 cells. PAT4 is predominantly
associated with the Golgi apparatus in a range of cell types, and in situ proximity ligation analysis shows that PAT4 interacts with
both mTORC1 and its regulator Rab1A on the Golgi. These ﬁndings, together with other studies, suggest that differentially
localised intracellular amino-acid transporters contribute to the activation of alternate forms of mTORC1. Furthermore, our data
predict that colorectal cancer cells with high PAT4 expression will be more resistant to depletion of serine and glutamine,
allowing them to survive and outgrow neighbouring normal and tumorigenic cells, and potentially providing a new route for
pharmacological intervention.
Oncogene (2016) 35, 3004–3015; doi:10.1038/onc.2015.363; published online 5 October 2015
INTRODUCTION
During cancer growth, tumour cell adaptation is driven by adverse
microenvironmental conditions such as hypoxia and starvation.1
Mechanistic target of rapamycin complex 1 (mTORC1) responds to
both local nutrient status and growth factor signalling through
phosphatidylinositol 3-kinase to regulate protein synthesis and
cellular homeostasis, thereby modulating cancer cell growth,
metabolism and metastasis.2–4 However, attempts to block
tumour growth using the allosteric mTOR inhibitor rapamycin or
its analogues have met with limited success.5 Although these
drugs strongly reduce signalling to one of the two well-
characterised mTORC1 targets, ribosomal protein p70-S6 kinase
1 (S6K1), they often have more limited effects on the other,
eukaryotic translation initiation factor 4E-binding protein 1
(4E-BP1), a negative regulator of eukaryotic initiation factor 4E
(eIF4E)6,7 implicated in metastatic growth.8,9 This resistance can
sometimes be circumvented by using adenosine triphosphate
(ATP)-competitive mTOR inhibitors,5–7 which also block the other
mTOR kinase-containing complex, mTORC2. Nonetheless, how
changes in mTOR structure10 or mTOR regulators modulate
rapamycin sensitivity remains of considerable interest.
Members of the proton-assisted amino-acid transporter (PAT) or
solute-linked carrier 36 (SLC36) family11 were identiﬁed as positive
regulators of growth and mTORC1 signalling through an
in vivo genetic overexpression screen in ﬂies.12,13 These effects
were shown to be conserved by characterisation of the two
ubiquitously transcribed human PATs, PAT1 (SLC36A1) and PAT4
(SLC36A4).14 The prototypic PAT family member, PAT1, is a
lysosomal amino-acid transporter (AAT).15,16 In rapidly growing
cells, it is located at the surface of nutrient-rich late endosomal
and lysosomal (LEL) compartments,13 where mTOR accumulates in
response to amino-acid stimulation. The recruitment of mTOR
requires assembly of a multiprotein complex, which includes
Raptor, a heterodimeric pair of Ras-related Rag GTPases, the
pentameric Ragulator, and the vacuolar-H+-ATPase proton
pump at the compartment surface (reviewed in Bar-Peled
and Sabatini2 and Malik et al.2,3). PAT1 also interacts with
this complex to promote mTOR localisation on LELs and
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subsequent mTORC1 signalling. Amino-acid sensing by the PATs
may involve transport or signalling via a so-called ‘transceptor’
mechanism.4,13,17
Recent studies have identiﬁed an AAT in the related
SLC38 family, SLC38A9, which also interacts on LELs with the
mTORC1-regulatory machinery, potentially in response to
arginine,18,19 suggesting that different LEL-located, mTORC1-
regulatory AATs may sense different amino acids. Furthermore,
the identiﬁcation of molecules such as Golgi-localised Rab1A,20
and ADP ribosylation factor Arf121 and phospholipase D22,23
as regulators of Rag-independent, mTORC1 activation, suggests
that other amino-acid-sensing mechanisms remain to be
discovered.
Here we investigate PAT4 function in colorectal cancer.
Colorectal cancers are frequently rapamycin-resistant6 and
often metastatic, seriously impacting on clinical outcome.24,25
We show that PAT4 upregulation is associated with
cancer progression. By using an inducible PAT4 shRNA knock-
down in HCT116 colorectal cancer cells, we ﬁnd that
PAT4 responds to two rapidly metabolised, non-essential amino
acids, glutamine and serine,26,27 to drive rapamycin-resistant,
mTORC1-mediated cell proliferation. Furthermore, we provide
evidence that PAT4 interacts with Rab1A and mTORC1 on the
Golgi, suggesting a role in amino-acid-sensing from this
compartment.
RESULTS
Validation of a novel PAT4 monoclonal antibody
We generated a highly speciﬁc mouse monoclonal antibody
against PAT4 (antibody Pat4/9/H10). Staining with this antibody
revealed that PAT4 was localised to an asymmetric perinuclear
region in formalin-ﬁxed, parafﬁn-embedded 786-O renal cancer
cells, which express high PAT4 levels, and lost in 786-O cells
transfected with PAT4 small interfering RNA (siRNA) (Figures 1a
and b). Bands of 60–75 kDa molecular weight were observed on
western blots of cell lysates (Figure 1c) and strongly reduced after
PAT4 knockdown, conﬁrming antibody speciﬁcity. This smear
resolved into a band of ~ 30 kDa after pretreatment of lysates with
the glycosidase, peptide-N-glycosidase F (PNGase F), smaller than
the predicted 55 kDa molecular weight (Figure 1d).
High PAT4 expression is associated with poor outcome in
colorectal cancer patients
To test whether PAT4 expression is altered in human colorectal
cancer, we stained primary tumour tissue microarrays from 107
patients, who had been treated by surgical resection only. The
intensity of cytoplasmic staining was scored by a pathologist (CS)
into three categories (Figures 2a and b; see Materials and
methods), all of which were higher than normal colorectal
epithelium. Statistical analysis showed no association between
Figure 1. Validation of an ‘in-house’-generated anti-PAT4 monoclonal antibody. (a and b) Formalin-ﬁxed, parafﬁn-embedded 786-O cells
incubated with PAT4 monoclonal antibody (Pat4/9/H10) and visualised with 3,3'-diaminobenzidine (DAB). There is an obvious perinuclear
region of staining visible in most cells treated with the scrambled control siRNA (a). This staining is absent when the PAT4 transcript is knocked
down using an siRNA against PAT4 (si435; Heublein et al.;14 b). (c) Western blot analysis of serial dilutions of cell lysates (15, 7.5 and 3.8 μg of
protein) produced from pools of 786-O cells carrying an IPTG-inducible shPAT4 (43587; shPAT4) probed with PAT4 monoclonal antibody Pat/9/
H10. This reveals a set of bands from 60–75 kDa that is strongly reduced by IPTG-induced PAT4 knockdown (+IPTG), suggesting that they are
PAT4-speciﬁc. Western blots were also probed with an anti-tubulin antibody as a loading control. (d) Western blot of cell lysates from 786-O
cells and from a GFP-PAT4-overexpressing HEK-293 cell line treated with PNGase F before electrophoresis to remove glycosyl groups. This
resolves the crossreacting molecules seen in untreated cell lysates into more speciﬁc bands migrating at ~ 30 and 50 kDa, respectively, smaller
than the predicted molecular weights of 55 kDa (PAT4) and 85 kDa (GFP-PAT4), a phenomenon also reported for other transmembrane
proteins.43
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high PAT4 expression and standard clinical or pathological
variables, including site of tumour, tumour stage, nodal or distal
metastases, age, lymphatic, vascular or neural invasion, differ-
entiation or gender (Supplementary Table S1).
In univariate analyses, high PAT4 levels (P= 0.01) as well as high
tumour stage (Po0.01), tumour stage score (Po0.01), the
presence of bowel perforation (P= 0.02), neural invasion
(Po0.01), nodal (Po0.01) and synchronous metastasis
(Po0.01) signiﬁcantly correlated with shorter relapse-free survival
(Supplementary Table S2). Patients with cancers that had higher
PAT4 expression had a signiﬁcantly shorter mean relapse-free
survival compared with those with lower levels (Po0.01;
Figures 2c and d). Additionally, higher PAT4 levels showed
statistical signiﬁcance in multivariate survival analysis (Po0.01;
Supplementary Table S3). The multivariate model included all
variables signiﬁcantly associated with relapse in univariate
analysis, apart from overall stage, as this is calculated from
tumour stage (T), nodal metastases (N) and distant metastases (M)
stages. We conclude that increased PAT4 levels are associated
with worse prognosis in patients with colorectal cancer.
PAT4 regulates HCT116 cell proliferation
To analyse PAT4 function in HCT116 colorectal cancer cells,
we generated stably transduced cell lines, each carrying one
of three different lentiviral constructs expressing a PAT4 short
hairpin RNA (shRNA) under isopropyl β-D-1-thiogalactopyranoside
(IPTG)-inducible control. For each construct, pooled cells repre-
senting many individual transduction events had reduced PAT4
transcript levels, as determined by quantitative real-time PCR
Figure 2. High expression of PAT4 predicts poorer relapse-free survival in colon cancer. In all, 107 patients with primary colonic carcinoma
were assessed for expression of PAT4 in their tumours and stratiﬁed according to PAT4 expression. (a and b) Representative images of low and
high PAT4 expression levels as determined by immunohistochemistry. Brown staining with diaminobenzidine indicates immunoreactivity. (c)
Kaplan–Meier curves compare high versus low levels of expression. P-value is the result of a log-rank test (Mantel–Cox). (d) Case processing
summary for high and low PAT4-expressing patients. The scale bar in (a) is 50 μm.
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(Supplementary Figure S1A). Two shRNAs, 49 384 and 49 387, were
selected for further study. To induce a uniformly strong PAT4
knockdown, single-cell clones were isolated from another
shRNA transduction, and named shPAT4(4.8) and shPAT4(7.1),
respectively (Supplementary Figure S1B). In vitro culture of these
clones together with HCT116 cells containing an IPTG-inducible,
non-targeting shRNA (shNT) gene revealed that IPTG induction
speciﬁcally inhibited proliferation of shPAT4-expressing cells
(Po0.05; Figure 3a) with no signiﬁcant effect on cell death
(Supplementary Table S4).
PAT4 promotes human tumour growth in xenograft models
To assess the role of PAT4 in tumour growth, pooled clones of
HCT116 cells carrying shPAT4(49 387), were used in xenograft
experiments. We reasoned that the variable level of PAT4
knockdown in these cells might better model changes taking
place in heterogeneous tumours expressing different levels of
PAT4. The effect on tumour growth of IPTG-induced PAT4
knockdown in shPAT4 HCT116 cells was assessed in mice over a
60-day period. Immunodeﬁcient mice were provided with IPTG in
their drinking water to induce shRNA expression. IPTG did not
alter the size of tumours formed from shNT cells (Figure 3b).
However, IPTG-induced shPAT4 expression reduced tumour
growth signiﬁcantly compared with non-induced shPAT4 controls
(Figure 3c; Po0.01). In addition, shPAT4 induction extended
median survival time of mice from 36 to 50 days (ratio: 0.72; 95%
conﬁdence interval of ratio: 0.36–1.07; Gehan–Breslow–Wilcoxon
Test, P= 0.008; Figures 3d and e). Induction of PAT4 knockdown in
a second experiment also signiﬁcantly reduced mean tumour
volume (Po0.05) and improved animal survival (Po0.05),
demonstrating that PAT4 promotes HCT116 tumour growth
in vivo.
PAT4 regulates a rapamycin-resistant form of mTORC1
To determine how PAT4 knockdown might inhibit tumour growth,
we analysed mTORC1 signalling in stably transfected HCT116
clones carrying inducible PAT4 shRNAs, shPAT4(4.8) and shPAT4
(7.1), and in the non-targeting clone, shNT. PAT4 protein is
expressed at much lower levels in HCT116 cells compared with
786-O cells, thus lysates from large pools of HCT116 cells were
pretreated with PNGase F to detect PAT4, which resolved into a
speciﬁc 30 kDa band that was clearly reduced after IPTG addition
in knockdown cells (Figures 4a and b).
IPTG-induced PAT4 knockdown selectively reduced the most
highly phosphorylated form of 4E-BP1, designated the γ-band on
western blots,28 whereas levels of less phosphorylated forms
increased (Figures 4c and f). Human 4E-BP1 has at least eight
phosphorylation sites.28 Phosphorylation of 4E-BP1 at Ser65, a key
residue for eukaryotic initiation factor 4E binding,29 is typically
required to form the γ-band. An anti-phospho-Ser65-4E-BP1
antibody veriﬁed that phosphorylation of this residue (p-S65-4E-
BP1) was strongly decreased by PAT4 knockdown. In contrast,
overall phosphorylation of p-T37/46-4E-BP1 was maintained, but
distributed between multiple 4E-BP1 bands after knockdown.
PAT4 knockdown either had no effect on S6K1 (p-T389-S6K1)
and S6 (p-S240/244-S6) phosphorylation (Figures 4c and d),
or sometimes led to a modest reduction in p-S240/244-S6
(e.g., Figure 5a and Supplementary Figure S2C).
To conﬁrm that PAT4 knockdown was not altering 4E-BP1
phosphorylation by inhibiting upstream phosphatidylinositol
3-kinase/Akt signalling, levels of phosphorylated mTORC2-
regulated Akt (p-S473-AKT) were assessed; no change was
observed (Figures 4c and d). Phosphorylation of extracellular
signal-regulated kinase (ERK) mitogen-activated protein kinase
(p-T202/Y204-ERK) by oncogenic forms of KRAS has also been
associated with resistance to mTOR kinase inhibitors in colorectal
Figure 3. PAT4 regulates the growth of HCT116 cells in vitro and in vivo. (a) Proliferation of clones of HCT116 cells stably transduced with one of
two independent IPTG-inducible shRNA constructs targeting PAT4, namely shPAT4(4.8) and shPAT4(7.1), or the IPTG-inducible non-targeting
control construct (shNT) was measured in the presence and absence of IPTG (n= 3). (b and c) Mean growth curves (± s.e.m.) of human HCT116
tumour xenografts in immunodeﬁcient mice carrying pools of cells transduced with shNT (b) with (empty circles) or without (ﬁlled squares)
IPTG induction, or shPAT4-transduced HCT116 cells (c) with (empty squares, outlined in red) or without (ﬁlled squares) IPTG induction (n= 7).
Data in (b and c) were analysed by unpaired two-tailed independent Student’s t-test. (d and e) Kaplan–Meier survival curves of seven animals
with and without IPTG induction of shNT- (d) and shPAT4-containing (e) HCT116 tumours; log-rank (Mantel–Cox) test: P= 0.019 for (e). For
shPAT4-inducible cells, all but one of the seven non-induced mice (ﬁlled squares) needed to be killed within 36 days (median survival time of
36 days), whereas all seven induced mice (empty squares, outlined in red) were killed from 38 days onwards with a median survival time of
50 days. Cell proliferation experiment was repeated three times. *Po0.05, **Po0.01.
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cancer.30 HCT116 cells carry an oncogenic KRAS-G13D allele, but
PAT4 knockdown did not reduce ERK phosphorylation (Figures 4c
and d), suggesting that it does not act through ERK to regulate
mTORC1.
The selective action of PAT4 knockdown on 4E-BP1 phosphor-
ylation versus the S6K/S6 signalling arm of the mTORC1 pathway
is complementary to the effects reported with rapamycin in these
cells,6 where 4E-BP1 γ-phosphorylation is particularly resistant to
this drug. Even at rapamycin concentrations that essentially
blocked S6 phosphorylation, residual 4E-BP1 γ-phosphorylation
was observed, as well as lower-molecular-weight 4E-BP1 phos-
phorylated on Ser65 (Figure 5a and Supplementary Figures S2A
and B). However, when rapamycin and PAT4 knockdown were
combined, the γ-form of phosphorylated 4E-BP1 and remaining
p-S65-4E-BP1 bands were almost completely lost (Figures 5a and b
and Supplementary Figures S2C and D). Unlike rapamycin, an ATP-
kinase inhibitor of mTOR, PP242, strongly affected both
4E-BP1 γ-phosphorylation and S6K activity in HCT116 cells
(Supplementary Figure S2E). Taken together, these ﬁndings
suggest that in HCT116 cells essentially all 4E-BP1 γ-phosphoryla-
tion is mTORC1-dependent (see also Ducker et al.30), but that
some phosphorylation is rapamycin-resistant and regulated by
PAT4. Importantly, rapamycin and PAT4 knockdown also had
additive effects on HCT116 cell proliferation (Figure 5c), demon-
strating they inhibit different mTORC1 complexes, which both
have a role in cell proliferation.
To test the link between PAT4 expression and rapamycin
resistance, we overexpressed a green ﬂuorescent protein
(GFP)-tagged form of PAT4 in HEK-293 cells. We have previously
shown in these cells that siRNA-induced knockdown of PAT4
reduces both 4E-BP1 and S6K/S6 phosphorylation, and this was
conﬁrmed using shRNA knockdown (Supplementary Figure S3).
We observed that 4E-BP1 hyperphosphorylation shows some
rapamycin resistance in HEK-293 cells (Supplementary Figure S2F).
Strong overexpression of GFP-PAT4, which produced several
protein bands resolving to a 50 kDa band on western blots after
PNGase pretreatment (Figure 1d), increased rapamycin resistance
of hyperphosphorylated, p-Ser65-4E-BP1 (Figures 5d and e). This
suggests that high PAT4 levels can induce resistance to rapamycin
in multiple different cell types.
PAT4-dependent sensitivity of rapamycin-resistant mTORC1 to
glutamine and serine
As PATs are implicated in amino-acid-dependent mTORC1
activation, we hypothesised that PAT4 might sense levels of
speciﬁc amino acids that regulate rapamycin-resistant mTORC1.
We starved HCT116 cells of speciﬁc amino acids, including two
non-essential amino acids required for HCT116 growth.
Non-essential serine is diverted into glycolysis, whereas glutamine
fuels the tricarboxylic acid cycle via glutaminolysis in cancer cells,
including HCT116 cells.26,27,31 Reducing either amino acid,
particularly glutamine, over 4 h had a stronger inhibitory effect
on 4E-BP1 hyperphosphorylation compared with loss of any
essential amino acid (Figure 6a).
If some of the selective effects of glutamine and serine on
4E-BP1 are mediated via a PAT4-dependent sensing mechanism,
we reasoned that modest changes in PAT4 levels might alter the
sensitivity of HCT116 cells to glutamine and serine starvation. Our
PAT4 knockdown clones displayed leaky IPTG-independent shRNA
knockdown (Supplementary Figure S1B), which normally did
not affect 4E-BP1 phosphorylation (Figure 5a) or proliferation
(Figure 3a). We tested the amino-acid sensitivity of these cells in
the absence of IPTG. 4E-BP1 hyperphosphorylation was more
sensitive to reduction in glutamine and serine levels in both
shPAT4(4.8) (Figures 6b and c) and shPAT4(7.1) (Supplementary
Figures S4) clones, indicating that PAT4 is involved in the sensing
of these metabolically important amino acids. Interestingly,
S6 phosphorylation also appeared to be more sensitive to
reduced glutamine and serine in these experiments, suggesting
either that rapamycin-resistant mTORC1 can directly or indirectly
modulate S6K activity under certain conditions or that starvation
affects the speciﬁcity of PAT4 for rapamycin-resistant mTORC1.
Combining glutamine or serine starvation with rapamycin
treatment had a greater effect on 4E-BP1 hyperphosphorylation
Figure 4. PAT4 selectively affects the mTORC1 target 4E-BP1.
Western blots of protein extracts from HCT116 cells carrying either
IPTG-inducible shNT or shPAT4(4.8) (a and c) or shNT and shPAT4(7.1)
constructs (b and d) cultured in the presence and absence of IPTG.
(a and b) PAT4 knockdown reduces the level of PAT4 protein
detected following incubation of cell lysates with PNGase F before
electrophoresis. (c–f) PAT4 knockdown signiﬁcantly reduced the
level of the most phosphorylated γ-form of 4E-BP1, visualises both
with an anti-phospho-Ser65-4E-BP1 (p-S65-4E-BP1) antibody and
also as the upper band with a pan-4E-BP1 antibody (arrow;
quantiﬁed in three independent experiments as a proportion of
total 4E-BP1 staining in histograms in (e) and (f), respectively).
Phospho-S6K (p-T389-S6K1), phospho-S6 (p-S240/244-S6), phospho-
Akt (p-S473-AKT) and phospho-ERK (p-T202/Y204-ERK) levels are
essentially unaffected by PAT4 knockdown. Blots were probed with
an anti-tubulin antibody as a loading control. Effects were
reproduced in three separate experiments. *Po0.05; **Po0.01.
PAT4 controls the amino-acid sensitivity of mTORC1 from the Golgi
S-J Fan et al
3008
Oncogene (2016) 3004 – 3015 © 2016 Macmillan Publishers Limited
compared with either treatment alone (Figures 6d and e),
supporting our conclusion that these amino acids are sensed by
PAT4-regulated, rapamycin-resistant mTORC1.
Golgi-localised PAT4 interacts with mTORC1
Immunoﬂuorescence staining of HCT116 cells revealed that PAT4
is concentrated on and adjacent to the trans-Golgi network
(Figure 7a). A similar localisation was observed in 786-O cells
(Supplementary Figure S5A). A previous report also suggested that
overexpressed PAT4 in HEK-293T cells is not on LELs.32
Interestingly, although under normal culture conditions, most
mTOR is localised around the LELs, some colocalisation with the
trans-Golgi network was also observed (Figure 7b), raising the
possibility that it might be associated with PAT4 in this
compartment.
To investigate this further, we used rapamycin-resistant HEK-
-293 cells expressing GFP-tagged PAT4 (Figure 5d). GFP-PAT4 also
localised on and around the trans-Golgi network (Figure 8a). Golgi-
localised Rab1A, a monomeric GTPase involved in membrane
trafﬁcking events, has recently been implicated in amino-acid-
dependent activation of mTORC1 from the Golgi.20 We tested
Figure 5. PAT4 regulates a rapamycin-resistant form of mTORC1 in HCT116 cells and increases rapamycin resistance in HEK-293 cells. (a and b)
Clones of HCT116 cells carrying the IPTG-inducible PAT4 shRNA construct, shPAT4(4.8), and the IPTG-inducible non-targeting control construct,
shNT, were cultured for 5 days in the absence or presence of IPTG and, if required, treated with rapamycin for the last 24 h. Rapamycin (3 nM;
see Supplementary Figures S2A and B) strongly reduces phospho-S6 levels (p-S240/244-S6), and partially affects the Ser65-phosphorylated
4E-BP1 (p-S65-4E-BP1) γ-band (arrow). This rapamycin-resistant phospho-4E-BP1 γ-band is almost completely lost after PAT4 knockdown (b).
(c) shPAT4(4.8) cells and shNT controls were cultured for 8 days in the absence or presence of IPTG and treated with rapamycin for 3 days. Cells
were then counted revealing reduced proliferation for both cell lines in the presence of rapamycin, and also for shPAT4(4.8) in the presence of
IPTG (n= 3). The combination of both rapamycin and IPTG leads to further reduction in the cell number of shPAT4(4.8). (d and e) Normal
HEK-293 cells or cells stably transfected with a constitutively expressed GFP-PAT4 construct were cultured for 24 h in the presence or absence
of 100 nM rapamycin (see Supplementary Figure S2F), and then cell lysates analysed by western analysis. GFP-PAT4 expression reduces the
effect of rapamycin on the γ-phosphorylated 4E-BP1 band (e), but not phospho-S6 (p-S240/244-S6), phospho-Akt (p-S473-AKT) or phospho-
ERK (p-T202/Y204-ERK). All blots were probed with an anti-tubulin antibody as a loading control. (*Po0.05; n= 3). The cell proliferation
experiment was repeated three times. NS, not signiﬁcant.
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whether Rab1A might interact with PAT4. We used the proximity
ligation assay (PLA), which detects speciﬁc protein–protein
interactions in situ, when antibodies recognising these molecules
are in close proximity.33 Although anti-Rab1A staining primarily
localised to the cis-Golgi (Figure 8b), Rab1A and GFP antibodies
produced a PLA signal on an adjacent compartment (Figure 8c),
which was not present in cells that did not express GFP-PAT4
(Supplementary Figure S5B). This signal frequently overlapped
with GFP-PAT4 and was partly within the trans-Golgi network
(Figure 8d), suggesting that Rab1A and PAT4 can interact on the
Golgi. In addition, PLA using either anti-mTOR (Figure 8e) or anti-
Raptor (Figure 8f and Supplementary Figure S5C) antibodies with
anti-GFP also produced a speciﬁc signal primarily in GFP-PAT4-
containing compartments that included the trans-Golgi network.
This indicates that mTORC1 interacts with PAT4 on the Golgi,
consistent with the idea that PAT4 can regulate mTORC1 activity
from this compartment.
DISCUSSION
Although resistance of mTORC1 to inhibitors can be partly
explained by differential in vitro sensitivity of substrate target
sites,34 increasing evidence indicates there are also different
mTORC1 complexes in cancer cells,20–23,35 which may make them
differentially sensitive to drugs such as rapamycin. In this study,
we demonstrate that PAT4 regulates rapamycin-resistant mTORC1
in HCT116 cells and can induce increased rapamycin resistance
when overexpressed in HEK-293 cells. PAT4 and rapamycin-
resistant mTORC1 are essential for normal cell proliferation in vitro.
Furthermore, PAT4 expression levels are predictive of early relapse
in colorectal cancer, suggesting a pathophysiological role in the
acquisition of more aggressive tumour phenotypes.
Our ﬁndings support a model in which rapamycin-resistant and
-sensitive forms of mTORC1 can be independently controlled, and
provide a new genetic tool to separate these two signalling
functions (Figure 9). Rapamycin-resistant mTORC1 selectively, but
Figure 6. Glutamine and serine selectively regulate PAT4-dependent rapamycin-resistant mTORC1 signalling in HCT116 cells. (a) HCT116 cells
were starved of the essential amino acids, glycine (Gly), isoleucine (Ile), leucine (Leu), threonine (Thr) and tryptophan (Trp), and the non-
essential amino acids, serine (Ser) and glutamine (Gln), for 4 h in separate cultures, and then proteins extracted and subjected to western
blotting. After this time, glutamine depletion produces the greatest reduction in γ-phosphorylation of 4E-BP1 (arrow); serine depletion also
induces a more modest shift. (b) Clones of HCT116 cells carrying the IPTG-inducible PAT4 shRNA constructs, shPAT4(4.8), and the IPTG-
inducible non-targeting control construct, shNT, were exposed to culture medium containing different concentrations of glutamine for 4 h in
the absence of IPTG. Under these conditions, shPAT4(4.8) cells express about 50% of normal PAT4 mRNA levels (Supplementary Figure S1B)
because of leaky PAT4 shRNA transcription. As glutamine concentration falls, a greater reduction in γ-phosphorylation of 4E-BP1 is apparent in
shPAT4(4.8) cells. S6 phosphorylation also seems to be affected at low glutamine concentrations. (c) Same experiment as (b), except different
levels of serine in the culture medium. Again, shPAT4(4.8) cells have lower 4E-BP1 γ-phosphorylation at reduced concentrations of serine. (d
and e) Rapamycin-treated HCT116 cells subjected to different levels of glutamine (d) and serine starvation (e), over 4 h, show a greater
reduction in γ-phosphorylation of 4E-BP1.
PAT4 controls the amino-acid sensitivity of mTORC1 from the Golgi
S-J Fan et al
3010
Oncogene (2016) 3004 – 3015 © 2016 Macmillan Publishers Limited
not exclusively, regulates 4E-BP1 hyperphosphorylation, which is
also speciﬁcally targeted by P53 activation in murine erythroleu-
kemia cells,27 further supporting the idea that it is a distinct
complex. However, this selective effect (Figure 4 and
Supplementary Figure S2C) is not universal. In other cell types,
PAT4 primarily appears to regulate an mTORC1 complex control-
ling 4E-BP1 and S6K (Supplementary Figure S3; Heublein et al.14),
suggesting that cell-type-speciﬁc regulatory factors or PAT4
expression levels modulate this transporter’s speciﬁcity in
controlling mTORC1. Indeed, it is only upon PAT4 overexpression
that HEK-293 cells exhibit detectable PAT4-dependent rapamycin
resistance (Figure 5d).
It has been suggested that PAT4 regulates mTORC1 signalling
by transporting amino acids across the plasma membrane.36
However, this seems unlikely in our cell models for three reasons:
ﬁrst, cell surface PAT4 protein levels are very low (Figures 1a, 7
and 8);32,36 second, PAT4 appears to be a low-capacity
transporter;37 third, it is difﬁcult to explain how a cell surface
transporter might affect only rapamycin-resistant mTORC1. We
favour a model where PAT4 interacts with mTOR on the Golgi,
although it may also regulate mTORC1 from other subcellular
compartments.
Our study also revealed selective sensitivity of the mTORC1
target 4E-BP1 in HCT116 cells to reduction of two non-essential
amino acids, glutamine and serine, but not to the mTORC1
regulator leucine, whose intracellular levels can be modulated by
glutamine.38 The Arf1 GTPase, which regulates trafﬁcking in
multiple compartments, including the Golgi, has also recently
been implicated in glutamine sensing by mTORC1.22 A key
question is whether PAT4 and Arf1 are involved in a common
mTORC1-regulatory mechanism. As PAT4’s amino-acid speciﬁcity
is different to arginine-sensitive, mTORC1-regulatory SLC38A918,19
and PAT1,15 it seems likely that a range of AATs may determine
the sensitivity of mTORC1 to different amino acids. The unique
N-terminal domain of SLC38A9 appears to bind the Ragulator
complex with higher afﬁnity compared with other transporters.18
SLC38A9 also interacts at lower afﬁnity with the vacuolar-H+-
ATPase through sequences including its transmembrane domains,
which share similarity with other SLC38 and SLC36 (PAT) family
members. This may explain why several of these transporters can
regulate mTORC1, but some, such as PAT4, cannot pull down
other mTORC1 supercomplex components, even though PLA
indicates they interact in situ.
The PAT4-dependent sensitivity of 4E-BP1 hyperphosphoryla-
tion to 4 h of glutamine or serine starvation probably reﬂects the
rapid metabolism of these two non-essential amino acids in
HCT116 cells.23,27 Despite its name, when heterologously
expressed in Xenopus oocytes, PAT4 can transport amino acids
via a non-proton-coupled mechanism. It appears to have a very
high substrate afﬁnity, but low capacity, for proline and
tryptophan.37 Several other amino acids, including glutamine
and serine, bind with lower afﬁnity, and can compete with
high-afﬁnity PAT4 substrates, although they may not be
transported. This could provide a transport-independent,
amino-acid-sensing ‘transceptor’ mechanism, in keeping with
previous suggestions for the PATs.17 Cells would become more
resistant to depletion of highly metabolised amino acids
by expressing more PAT4, explaining the clinical data from
colorectal cancer patients.
In conclusion, our study suggests that pharmacological inhibi-
tion of an upstream mTORC1 activator such as PAT4 in colorectal
cancer could complement the actions of rapamycin, by blocking a
rapamycin-resistant, 4E-BP1-selective pathway. PAT4 may also




HCT116 cells were cultured in McCoy’s 5A modiﬁed medium (Gibco,
Invitrogen, Paisley, UK) containing 10% foetal calf serum (Gibco,
Invitrogen), unless otherwise speciﬁed. The 786-O and HEK-293 cells were
cultured in 10% foetal calf serum-containing Dulbecco's modiﬁed Eagle's
medium. Cells were incubated at 37°C in 5% CO2. Rapamycin treatment
was carried out 24 h after seeding. Cells were treated for 24 h typically, or
72 h for cell proliferation analysis, with 3 nM (HCT116) or 100 nM (HEK-293)
rapamycin, diluted from a stock solution in dimethyl sulfoxide (R8781;
Sigma, Gillingham, UK), or as speciﬁed for dose–response curves. Founder
cell lines were obtained from ATCC (LGC Standards, Teddington, UK) and
used within 6 months of resuscitation (o25 passages). si435 used to
knockdown PAT4 expression and the scrambled control siRNA (Figure 1)
were previously described in Heublein et al.14
Inducible shRNA-expressing lentiviruses
Sigma Mission lentiviral particles carrying the following clones:
TRCN0000043984, 5′-CCGGCCTTGATAAATGAGCAGAATTCTCGAGAATTCTG
CTCATTTATCAAGGTTTTTG-3′ (referred to as shPAT4(43 984)); TRCN000
0043985, 5′-CCGGCCTGGAGAGTAAAGTGTTTATCTCGAGATAAACACTTTACT
CTCCAGGTTTTTG-3′ (shPAT4(43 985)) and TRCN0000043987, 5′-CCGGC
CAGTATGTTGTCAGGAACATCTCGAGATGTTCCTGACAACATACTGGTTTTTG-3′
(shPAT4(43 987)) and a non-targeting control construct (SHC312V; shNT) in
the IPTG-inducible lentiviral vector pLKO IPTG_1xLacO were transduced
into HCT116 cells. Although shPAT4(43 984) partially overlaps with siRNA
(435), shPAT4(43 985) and (43 987) have no overlap with previously used
siRNAs.14 For most experiments, clone shPAT4(7.1) produced a stronger
knockdown compared with clone shPAT4(4.8), with greater effects on
proliferation and mTORC1 signalling.
Figure 7. PAT4 and mTOR are located on the Golgi in HCT116 cells. (a) Endogenous PAT4 (green) is expressed in compartments that include
the trans-Golgi network (TGN46; red) in HCT116 cells. (b) Although most mTOR (green) is located on LAMP2-positive late endosomes and
lysosomes (blue) in HCT116 cells, some mTOR staining also overlaps with the trans-Golgi network (red; indicated by arrows in merged images).
DAPI (4',6-diamidino-2-phenylindole) marks the nucleus in (a) (blue) and (b) (white). Scale bars are 5 μm. Confocal channels are indicated as
follows in the merged images: green (G), blue (B) and red (R).
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Generation and induction of shRNA lines
Cells were transduced with lentiviral vectors at a multiplicity of infection of
three (viral particles to cells) in the presence of polybrene. Puromycin
selection began 2 days after transduction to generate pools of cells derived
from multiple transduction events. Single-cell clones were isolated soon
after transduction using the limiting dilution method. IPTG (100 μM) was
added for induction. IPTG-treated cells were preinduced for 5 days before
plating.
Figure 8. PAT4 interacts with Rab1A and mTORC1 on the Golgi. (a) GFP-PAT4 fusion protein (green) in HEK-293 cells shows a similar
subcellular localisation to HCT116 cells on the trans-Golgi (TGN46; red). An alternative cell at higher resolution is stained with the same
markers in (d). (b) Rab1A (blue) is localised primarily on the cis-Golgi, labelled by the GM130 marker (red). (c) In situ PLA (red) reveals
interaction between Rab1A (blue) and GFP-PAT4 (green) primarily associated with GFP-PAT4-containing compartments (overlap between
GFP-PAT4 and PLA signal is yellow in merge, top right panel; arrow). The PLA signal is also adjacent and partially overlapping with
compartments on which Rab1A is concentrated in merge of Rab1A and PLA, bottom right panel. Rab1A/PAT4 PLA signals are only
observed in GFP-PAT4-expressing cells (see Supplementary Figure S5B). (d) Some of the GFP-PAT4/Rab1a PLA-positive interacting
compartments (red) also appear to be partly or entirely labelled by trans-Golgi network marker TGN46 (blue; arrow), but not trans-Golgi
regions lacking GFP-PAT4. (e) PLA (red) reveals an interaction between mTOR (blue) and GFP-PAT4 (green) partially overlapping with GFP-
PAT4-containing compartments (yellow in merges containing green and red channels, including magniﬁed image in top right panel;
arrow). In the low magniﬁcation merge image, the two upper cells not expressing GFP-PAT4 do not give a PLA signal, indicating that this
assay speciﬁcally detects the GFP-PAT4/mTOR interaction. Blue and red channel merge (lower right-hand panel) reveals that mTOR
staining is often in close proximity to PLA signal, but is also found in many other locations within the cell. (f) PLA (red) reveals an
interaction (red) between Raptor and GFP-PAT4 (green), in and adjacent to compartments containing GFP-PAT4 (yellow overlap in merges
containing green and red channels, including magniﬁed image in top right panel; arrow and arrowheads). Blue and red channel merge
(lower right-hand panel) reveals that some PLA signals are adjacent or partially colocalise with the trans-Golgi (TGN, blue; arrowheads),
whereas others do not (arrow). Raptor/GFP-PAT4 PLA signals are only observed in GFP-PAT4-expressing cells (see Supplementary Figure
S5C). DAPI marks the nucleus in (a) (blue) and (b–f) (white) in the merge. Confocal channels are indicated as follows in the merged images:
green (G), blue (B) and red (R). Scale bars are 5 μm.
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Amino-acid starvation media
Medium was based on Dulbecco's modiﬁed Eagle's medium (11995-065;
Invitrogen), but made in-house, so that different amino acids could be
omitted individually. For glutamine, a medium lacking this amino acid was
already available (McCoy's 5A without glutamine (M8403; Sigma)). Cells
were starved of amino acids for 4 h.
Generation of GFP-PAT4 stable cell line
The PAT4 open reading frame from IMAGE Clone ID:531323 was
recombined into a pOPINE vector containing an in-frame C-terminal GFP
sequence (pOPINE-GFPc; gift from J Beale and S Newstead). The following
errors in the PAT4 cDNA sequence (compared with the annotated
transcript sequence) were corrected using the Quickchange Site-Directed
Mutagenesis Kit (Invitrogen): I209L (ATA-4CTA) H376P (CCT-4CAT) I429L
(ATA-4CTA). The PAT4-GFP fusion was ampliﬁed by PCR and cloned into
pcDNA3.1(+) at the KpnI and XbaI sites. Ampliﬁed PAT4 and GFP open
reading frames were recloned into pcDNA3.1(+) as a GFP-PAT4 fusion.
HEK-293 cells were transfected with this construct or the empty pcDNA3.1
(+) vector using Lipofectamine 2000 (Invitrogen). Stably transfected cells
were selected 48 h later using 800 μg/ml Geneticin (Gibco, Invitrogen), as
described in Heublein et al.14
Xenograft studies
All protocols were carried out under Project Licence 30/2771 following
Home Ofﬁce regulations39 using 6- to 7-week-old female BALB/c SCID nu/
nu mice (Harlan Sprague Dawley Inc., Bicester, UK). A total of 2.5 × 106
HCT116 cells in 50 μl serum-free medium and 50 μl Matrigel (BD
Bioscience, Oxford, UK) were subcutaneously injected into one ﬂank
(seven mice per group; animals not randomized and investigator not
blinded; numbers were based on previous xenograft studies). In all, 10 mM
IPTG (Carbosynth Inc., Compton, UK) was added to drinking water of
treated mice. Tumour growth was measured three times a week using
callipers and volume calculated from the formula 1/6π x length x width x
height. The experiment was repeated and produced similar signiﬁcant
reductions in growth and effects on survival time.
Quantitative real-time PCR
RNA extraction and quantitative real-time PCR were carried out as
described previously,14 with Ct values for PAT4 normalised against the
HPRT1 housekeeping gene.
Cell proliferation analysis
Cell proliferation experiments, each using a minimum of three wells, were
repeated three times. Where statistically signiﬁcant results were found,
these were observed on all occasions. Cells were counted according to the
methodology described in Heublein et al.14
Western blots
Protein lysates were routinely loaded on 10% polyacrylamide gels. For
immunoblotting, the following primary antibodies were used at recom-
mended dilutions: phospho-S6K1 Thr308 (Cell Signalling Technology,
Hitchin, UK (CST; no.9205)), S6K1 (CST; no. 9202), phospho-Ser240/244-
ribosomal S6 protein (CST; no. 2215)), S6 ribosomal protein (CST; no. 2217),
phospho-Ser65-4E-BP1 rabbit polyclonal (CST; no. 9451), 4E-BP1 (CST; no.
9644), phospho-Ser473-Akt (CST; no. 4060), Akt (CST; no. 9272), phospho-
Thr202/Tyr204-p44/42 mitogen-activated protein kinase (Erk1/2; CST; no.
4370), p44/42 mitogen-activated protein kinase (Erk1/2; CST; no. 4695) and
α-tubulin (Sigma; no. T6199). They were detected with secondary
antibodies (Promega, Southampton, UK; nos. W401B and W402B) and
visualised using the SuperSignal West Pico Chemiluminescent Substrate Kit
(Thermoscientiﬁc, Loughborough, UK). PAT4 was deglycosylated with
PNGase F (New England Biolabs, Hitchin, UK; no. P0704) according to the
manufacturer’s instructions.
Generation of PAT4 monoclonal antibody
A monoclonal antibody against PAT4 was created by immunising mice
with a keyhole limpet haemocyanin-conjugated, cysteine-coupled peptide
(Severn Biotech Ltd., Kidderminster, UK) based on an antigenic amino-acid
sequence within the N terminus of PAT4 (REELDMDVMRPLINE-C).
Immunohistochemistry
The following commercial primary antibodies were used: mTOR
(CST; no. 2983; 1/100), LAMP2 mouse monoclonal (Abcam, Cambridge,
UK; ab25631; 1/100), TGN46 sheep polyclonal (Novus Biologicals,
Abingdon, UK; NB110-40767: 1/200), Rab1a rabbit monoclonal (CST; no.
13075; 1/100), GFP mouse monoclonal (Abcam; ab1218; 1/100), GM130
mouse polyclonal (Novus Biologicals; H00002801-B01P; 1/25), Raptor rabbit
polyclonal (Merck Millipore, Watford, UK; 09-217; 1/100) and secondary
antibodies raised in donkey (Jackson ImmunoResearch, West Grove, PA,
USA; 1/500). Cells were processed and imaged as described in
Ogmundsdottir et al.13 and Sancak et al.40 PLAs were performed using
the Duolink In Situ Orange Starter Mouse/Rabbit Kit (DUO92102; Sigma)
according to the manufacturer’s instructions.
For patient samples, slides were dewaxed and rehydrated with antigen
retrieval performed using citrate buffer pH 6.0 (Sigma-Aldrich, Gillingham, UK)
and a pressurised decloaking chamber (Biocare Medical, Concord, CA, USA).
The intensity of cytoplasmic staining was assessed by a pathologist (CS) on a
semiquantitative scale from 0 to 3. High levels of expression in tumour
sections were scored 3, and lower levels of expression scored 0, 1 or 2.
Immunohistochemistry was carried out as described previously.41
Parafﬁn-embedded tissue blocks from formalin-ﬁxed tumour samples
were sectioned, dewaxed and rehydrated using standard techniques and
4 μm sections.
Patient material
Formalin-ﬁxed and parafﬁn-embedded tissue was obtained with informed
consent from 111 patients with colon cancer treated by surgical resection at
the John Radcliffe Hospital (Oxford, UK) from 1997 to 2000. The sample size
was limited to 107 by availability of tissue with full clinicopathological data,
follow-up data and ethical approval. Use of tissue in this project was
approved by the Oxford Centre for Histopathological Research Panel (Project
number 12/A172) and the local Research Ethics Committee (C02.216). No
patients received preoperative chemotherapy. The average age at the time
of surgery was 71 years (range 37–96 years), 64 patients were male (58%)
and the average follow-up time was 4.1 years (as of January 2009). Based on
the tumour, nodal and distant metastases, cancer stage of patients at
resection was as follows: 10 patients (9%) stage 1; 55 patients (49%) stage 2;
35 patients (32%) stage 3 and 11 patients (10%) stage 4. All resections
resulted in clear margins. Relapse-free survival was deﬁned as time between
tumour resection and the ﬁrst documented recurrence of tumour at any site.
Patients who died from unrelated causes were excluded. Tissue microarrays
were assembled as described previously42 using two representative cores of
tumour and two representative cores of adjacent normal colonic mucosal
epithelium for each patient.
Figure 9. Schematic diagrams of rapamycin-sensitive and -resistant
mTORC1 complexes in HCT116 cells. S6K and 4E-BP1, a negative
regulator of eukaryotic initiation factor 4E(eIF4E), are the best
characterised downstream targets of mTORC1. Although rapamycin
treatment strongly inhibits S6K phosphorylation, it has a weaker
effect on 4E-BP1 γ-band phosphorylation at Ser65. Less phosphory-
lated forms of 4E-BP1 bind to eIF4E leading to translational
repression.8 Reducing PAT4 activity primarily affects the
rapamycin-resistant form of mTORC1. This leads to a reduction in
a Ser65-phosphorylated form of 4E-BP1, but has less effect on S6K
phosphorylation. Other AATs in the SLC36 (PAT) and/or SLC38 family
are likely to be involved in rapamycin-sensitive mTORC1 regulation,
for example, PAT1 and SLC38A9. PP242 is an mTORC1 ATP-kinase
inhibitor that acts on both the rapamycin-sensitive and -resistant
forms of mTORC1. Arrows signify positive signals and cross-bars
mark inhibitory signalling events.
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Statistics
All data (means ± s.e.m. (xenografts) or s.d (in vitro)) were analysed using
Excel or GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). For
tumour growth analysis, a parametric generalised linear model was
performed using GraphPad Prism 4.0b software. For western blot analysis,
cell proliferation and quantitative real-time PCR, statistical signiﬁcance was
determined using the Kruskal–Wallis one-way analysis of variance. All
in vitro experiments were replicated on at least three occasions. For patient
data, the χ2 test was used to determine association between PAT4
expression and categorical clinical variables (Supplementary Table S1). Cox
regression analysis was used to determine prognostic factors in univariate
(Supplementary Table S2) and multivariate survival models
(Supplementary Table S3). The log-rank (Mantel–Cox) test was used to
assess the signiﬁcance of differences in relapse-free survival between
Kaplan–Meier curves. Statistical analyses were performed using SPSS
Statistics (Version 21.0, IBM, New York, NY, USA).
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